Search results
Showing 391 to 405 of 985 results for drug therapy
SepsiTest assay for rapidly identifying bloodstream bacteria and fungi (DG20)
Evidence-based recommendations on the SepsiTest assay for rapidly identifying bloodstream bacteria and fungi
Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastases (TA412)
Evidence-based recommendations on radium-223 dichloride (Xofigo) for treating hormone-relapsed prostate cancer with bone metastases in adults.
Sodium zirconium cyclosilicate for treating hyperkalaemia (TA599)
Evidence-based recommendations on sodium zirconium cyclosilicate (Lokelma) for treating hyperkalaemia in adults.
Upadacitinib for treating moderate rheumatoid arthritis (TA744)
Evidence-based recommendations on upadacitinib (Rinvoq) for treating moderate active rheumatoid arthritis in adults.
This quality standard covers providing and organising cancer services for babies, children and young people (from birth to 24 years, although the upper age limit may vary). It describes high-quality care in priority areas for improvement.
View quality statements for QS55Show all sections
Sections for QS55
- Quality statements
- Quality statement 1: Multidisciplinary teams for young people
- Quality statement 2: Access to clinical trials
- Quality statement 3: Electronic prescribing of chemotherapy
- Quality statement 4: Psychological and social support
- Quality statement 5: Neuro-rehabilitation
- Quality statement 6: Follow-up and monitoring of late effects
- Quality statement 7: Fertility support
Evidence-based recommendations on inhaled corticosteroids for treating chronic asthma in adults and children aged 12 and over.
View recommendations for TA138Show all sections
Infliximab for the treatment of adults with psoriasis (TA134)
Evidence-based recommendations on infliximab for treating severe psoriasis in adults.
Antimicrobial prescribing: oritavancin for acute bacterial skin and skin structure infections (ES39)
Summary of the evidence on oritavancin for acute bacterial skin and skin structure infections (ABSSSI) in adults
Evidence-based recommendations on clopidogrel and modified-release dipyridamole for preventing occlusive vascular events in adults.
Sacral nerve stimulation for urge incontinence and urgency-frequency (IPG64)
Evidence-based recommendations on sacral nerve stimulation for urge incontinence and urgency-frequency. This involves placing electrodes and connecting them to an implantable pulse generator.
View recommendations for IPG64Show all sections
Sections for IPG64
Evidence-based recommendations on alpelisib (Piqray) with fulvestrant for treating hormone receptor-positive, HER2-negative, PIK3CA-mutated, locally advanced or metastatic breast cancer in adults.
Evidence-based recommendations on apremilast (Otezla) for treating active psoriatic arthritis.
Evidence-based recommendations on niraparib (Zejula) for treating relapsed, platinum-sensitive high-grade serous epithelial ovarian, fallopian tube or primary peritoneal cancer in adults.
NICE has developed a medtech innovation briefing (MIB) on Aptiva for painful diabetic neuropathy .
Evidence-based recommendations on ramucirumab (Cyramza) for treating advanced gastric cancer or gastro-oesophageal junction adenocarcinoma previously treated with chemotherapy.